




# Vaxxon<sup>®</sup> SRP<sup>®</sup> E. coli

THE FIRST AND ONLY INACTIVATED *E. COLI* VACCINE



## DECREASED INCIDENCE OF *E. COLI* PERITONITIS<sup>1</sup>

DECREASED MORTALITY, INCREASED LIVABILITY  
RESULTS IN **MORE EGGS** PER HEN HOUSED

**DEAD BIRDS DON'T LAY EGGS:** Improve bird health and welfare, while maximizing genetic potential with *E. coli* protection using SRP technology.

**REDUCED *E. COLI*:** Effective against mortality caused by *E. coli*.<sup>1</sup> Zero mortality was observed in vaccinated groups in our challenge studies. Effective against colonization of *E. coli* in the **reproductive tract**, internal organs and air sacs.

**SAFETY FIRST:** SRP vaccines are highly purified proteins, which often result in less flock setback and less tissue reaction than whole cell bacterins.

**INNOVATIVE:** First and only US-licensed *E. coli* vaccine in the market. Uses siderophore receptor and porin (SRP) proteins as immunogens.

Proteins are good immunogens – stimulating both cell-mediated and humoral immune systems.

Induces good anamnestic response.

Focuses host immune response to bacterial SRP irrespective of serotype.

SRPs are highly conserved between strains of bacteria.

- Specificity of SRP antibodies does not depend on the serotype of the challenge strain
- SRP antibodies will attach to multiple serotypes<sup>2</sup>



# EFFECTIVE AGAINST *E. COLI* CHALLENGE

This product has been shown to be effective against mortality caused by *E. coli*<sup>1</sup>


## IMPROVED OVERALL LIVABILITY OF VACCINATED FLOCK MAY RESULT IN:

- More eggs per hen-housed
- Healthier birds, therefore better egg production
- Maximized genetic potential

## THIS PRODUCT HAS BEEN SHOWN TO BE EFFECTIVE AGAINST COLONIZATION OF *E. COLI* IN THE REPRODUCTIVE TRACT, INTERNAL ORGANS AND AIR SACS:<sup>2</sup>

- Reduced incidence of peritonitis, air sacculitis, colibacillosis
- Reduced potential for secondary bacterial infections after viral infections or other stressors

*E. coli* colonization of tissues 7 days post-challenge (DPC)



\*Statistically significant  $P < 0.05$

REACH OUT TO A VAXXINOVA REPRESENTATIVE TO LEARN MORE

## REFERENCES:

1. productdata.aphis.usda.gov.
2. Data on file at Vaxxinova US.
3. Data on file. Study No. M2101. Vaxxinova US. May 2022.

